Industry news that matters to you.  Learn more

PDI, Inc. Subsidiary Interpace Diagnostics Sets New Precedent with Launch of ThyraMIR, First and Only MicroRNA Gene Expression Classifier for Thyroid Nodule Identification

PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, recently announced the launch of ThyraMIR™, the first and only microRNA (miRNA) gene expression classifier for identification of indeterminate benign and malignant thyroid nodules.

PDI, Inc. Subsidiary Interpace Diagnostics Announces New Data Supporting Use of ThyraMIR – First and Only MicroRNA Gene Expression Classifier – with ThyGenX Thyroid Oncogene Panel to Improve Identification of Both Benign and Malignant Thyroid Nodules

PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, recently announced new data supporting the use of combination platform testing with ThyraMIR™, the first and only microRNA expression classifier, and ThyGenX™ Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis. The study, presented at ENDO 2015: The 97th Annual Meeting & Expo of the Endocrine Society held March 5-8, 2015 in San Diego, CA, showed that benign or malignant nodules can be identified with high sensitivity and specificity resulting in clinically actionable negative predictive value (NPV) at 94% and positive predictive value (PPV) at 74%. The effect of combining nucleic acid sequencing with a gene classifier significantly improved the tests’ ability to correctly identify both benign and malignant nodules, potentially resulting in fewer unnecessary surgeries.

Veracyte and Fleury Announce Partnership to Make the Afirma® Gene Expression Classifier Available to Patients in Brazil

Veracyte, Inc. (Nasdaq: VCYT) and Fleury Medicine and Health recently announced a new partnership that will make Veracyte’s Afirma Gene Expression Classifier (GEC) available to patients in Brazil, helping to reduce unnecessary surgeries and potentially lower costs there as part of thyroid cancer diagnosis. Financial terms of the agreement were not disclosed.

Veracyte, Inc. Launches Afirma Malignancy Classifiers to Further Help Thyroid Nodule Patients Avoid Unnecessary Surgeries and Lower Healthcare Costs

Veracyte, Inc. (Nasdaq: VCYT) recently announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for medullary thyroid cancer (MTC) and the BRAF gene mutation and are intended to provide preoperative information to help guide surgical strategy for those patients who need surgery.

Life Technologies Launches Compendia Oncomine NGS Power Tools for Cancer Researchers, Discovers Novel Gene Fusions

Life Technologies Corporation (NASDAQ: LIFE) recently announced the introduction of Oncomine® Next Gen Sequencing Power Tools, an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed to date.